



## Development of High-performance Thin-layer Chromatography (HPTLC) Method for Quality Control of Actinidiae Fructus Vermiculatus

Kyung Ho Lee<sup>1,†</sup>, Geonha Park<sup>2,3,†</sup>, Sangjae Lee<sup>2</sup>, Yung Gyo Lee<sup>4</sup>, Minsik Choi<sup>4</sup>,  
Roun Lee<sup>2</sup>, and Young Pyo Jang<sup>1,2,3,4,\*</sup>

<sup>1</sup>Department of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

<sup>2</sup>Department of Oriental Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea

<sup>3</sup>Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

<sup>4</sup>Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

**Abstract** – In this study, we have successfully established a high-performance thin-layer chromatography (HPTLC) method for the quality assessment of Actinidiae Fructus Vermiculatus, known as Mokcheonryo(ja) in Korea. This is the dried vermiculate fruit of *Actinidia polygama* and *A. kolomikta*, as stipulated by the Korean Herbal Pharmacopoeia (KHP). However, the Korean herbal market often witnesses the inclusion and distribution of ‘Mihudo’, an alternative herbal product sourced from the dried fruits of *A. arguta*, belonging to the same botanical genus. This confluence has raised substantial apprehensions concerning the veracity of quality. In response to this concern, we have meticulously developed an HPTLC analytical methodology capable of differentiation between Mokcheonryo and Mihudo by exploiting their distinct chemical profiles. We identified umbelliferone as a key marker compound for Mokcheonryo and quantified the content of umbelliferone in each sample using a TLC scanner. Throughout this study, we confirmed distinct fingerprints for Mokcheonryo and Mihudo, providing a reliable means to differentiate between these two herbal medicines. Furthermore, the presence of umbelliferone in Mokcheonryo serves as an indicator compound for quality assessment. The proposed HPTLC method offers a practical and effective tool for ensuring the quality and authenticity of Mokcheonryo in the herbal market.

**Keywords** – High-performance Thin-layer Chromatography (HPTLC), Quality Control, Identification Test, Actinidia Fructus Vermiculatus, Umbelliferone

### Introduction

Herbal medicines have been a cornerstone in the prevention and treatment of human diseases for centuries.<sup>1</sup> Among the myriad of herbal medicines available, fruits from the *Actinidia* species have garnered global recognition for their palatable taste coupled with various pharmacological effects.<sup>2</sup> *Actinidia polygama* (Siebold & Zucc.) Planch. ex Maxim., a representative herbal medicine of the *Actinidia* species, is widely used, particularly in Korea and Japan.<sup>3</sup> Its vermiculate fruits, known as Mokcheonryo

(ja), are primarily used as medicinal materials in Korea.

Within the context of the Korean Herbal Pharmacopoeia (KHP),<sup>4</sup> both “Mokcheonryo (MCR)” and “Mokcheonryoja (MCRJ)” are collectively referred to as “Mokcheonryo”. However, it's important to note the nuanced distinction: MCR encompasses the branch and leaves, while MCRJ specifically denotes the fruit that has undergone insect consumption. In light of this differentiation, our study endeavors to provide distinct delineations for both MCR and MCRJ, with a particular emphasis on elucidating the attributes of MCRJ. The source plants of MCRJ are *Actinidia polygama* (Siebold & Zucc.) Planch. ex Maxim. and *A. kolomikta* (Maxim.) Maxim. (Family Actinidiaceae), while *A. arguta* (Siebold & Zucc.) Planch. ex Miq., although a congeneric plant, is not the source plant of MCRJ, thus it is considered a counterfeit. The

<sup>†</sup>These authors contributed equally to this work

\*Author for correspondence  
Young Pyo Jang, Department of Oriental Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea  
Tel: +82-2-961-9421; E-mail: ypjang@khu.ac.kr


fruit of *A. arguta* is used as a medicinal material known as “Mihudo (MHD)”, but the issue arises when it is distributed as a counterfeit of MCRJ.

MCRJ has earned traditional acclaim for its noteworthy efficacy in addressing ailments such as rheumatoid arthritis and gout. Additionally, it demonstrates effectiveness against conditions like abdominal pain and constipation.<sup>5</sup> In contrast, MHD, colloquially known as the hardy kiwi, is recognized for its potency in alleviating severe thirst, chest congestion, and fever, exerting beneficial effects on both the nerves system and the gastric tract. Its historical utilization is documented in traditional texts such as “Bonchogangmok”<sup>6</sup> and “Donguibogam”.<sup>7</sup>

According to the study by Khromykh et al.,<sup>8</sup> the principal compounds present in both extracts were 2-propenoic acid, pentadecyl ester, followed by squalene, 7,9-di-tert-butyl-1-oxaspiro(4,5)deca-6,9-dien-2,8-dione, octadecanoic acid, 2-oxo-methyl ester, ethylisoallocholate, and phytol. These compounds have gained recognition for their notable bioactive properties. Notably, the concentration of these compounds exhibited variations between the two species. This divergence accentuates the distinctive therapeutic profiles inherent to the herbal medicines MCRJ and MHD, thus underscoring the imperative for precise differentiation between them.

Currently, MCR(J) is not listed in other countries' pharmacopoeias, such as Japanese Pharmacopeia 18<sup>th</sup> (JP), Pharmacopeia of the People's Republic of China 2020 (ChP), Hong Kong Chinese Materia Medica Standards (HKCMMS), Taiwan Herbal Pharmacopeia (THP), etc., and its identification criteria are not established in KHP. This lack of standardization leads to a heavy reliance on morphological evaluation for quality control. The physical appearance of MCRJ and MHD is quite similar, albeit with certain differences. MCRJ presents a yellowish-brown, oval shape with a rough exterior. MHD, while also oval in shape, displays a color closer to black and its surface roughness is less pronounced compared to MCRJ. However, morphological evaluation alone may not be sufficient to ensure the quality and authenticity of herbal medicines. There have been cases where some herbal medicine markets erroneously sell ‘MHD’ as ‘MCRJ’. Fig. 1 displays representative appearances of MCRJ and MHD.

High-performance thin-layer chromatography (HPTLC) offers a solution to these challenges. HPTLC, an advanced form of thin-layer chromatography (TLC), is widely employed due to its simplicity, high speed, flexibility, and sensitivity.<sup>9-11</sup> It stands as an efficient and dependable technique for analyzing intricate mixtures found in herbal



**Fig. 1.** Representative morphologic features of the dried vermiculate fruits of *Actinidia polygama* (A) and the dried fruits of *A. arguta* (B).

medicines, revealing their chemical fingerprints.<sup>11</sup> It allows for the simultaneous analysis of multiple samples, providing a comprehensive overview of the chemical composition of the samples. Hence, HPTLC has traditionally been employed for the qualitative analysis of herbal medicines.<sup>12</sup> However, recent advancements in HPTLC technology have broadened its abilities, enabling it to not just identify but also measure specific compounds in herbal medicines.<sup>13,14</sup>

While the use of HPTLC for chemical fingerprinting of herbal medicines has been successfully implemented, there have been no studies reporting on the chemical fingerprint differentiation between MCRJ and MHD. Thus, our objective was to develop an HPTLC method to distinguish the chemical fingerprint between these two herbal medicines, providing a practical and effective tool for ensuring its quality and authenticity in the herbal market.

## Experimental

**Materials and reagents** – A total of 40 samples labeled as either MCRJ or MHD were purchased from Korean herbal medicine market. Their authenticity was confirmed by Dr. Young Pyo Jang, one of the authors. The information on the samples is shown in Table 1 and morphologic images are provided in supplementary data (Fig. S1 and Fig. S2). Umbelliferone (7-hydroxycoumarin, CAS 93-35-6, purity 99.0%) was purchased from Sigma-Aldrich (Steinheim, Germany).

For a system suitability test (SST), the Universal HPTLC mix (UHM)<sup>15,16</sup>, which consists of guanosine, sulisobenzone, thymidine, paracetamol, phthalimide, 9-hydroxyfluorene, thioxanthen-9-one and 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol, was used. The UHM was provided by CAMAG (Muttens, Switzerland). Silica gel 60 F<sub>254</sub> HPTLC plate (20 × 10 cm) and Silica gel 60 HPTLC plate (20 × 10 cm) were sourced

**Table 1.** The details information of the samples

No.	Sample	Medicinal parts	Origin	No.	Sample	Medicinal parts	Origin
01	<i>A. Polygama</i>	Vermiculate fruits	Korea	21	<i>A. Arguta</i>	Fruits	Korea
02	<i>A. Polygama</i>	Vermiculate fruits	Korea	22	<i>A. Arguta</i>	Fruits	Korea
03	<i>A. Polygama</i>	Vermiculate fruits	Korea	23	<i>A. Arguta</i>	Fruits	Korea
04	<i>A. Polygama</i>	Vermiculate fruits	Korea	24	<i>A. Arguta</i>	Fruits	Korea
05	<i>A. Polygama</i>	Vermiculate fruits	Korea	25	<i>A. Arguta</i>	Fruits	Korea
06	<i>A. Polygama</i>	Vermiculate fruits	Korea	26	<i>A. Arguta</i>	Fruits	Korea
07	<i>A. Polygama</i>	Vermiculate fruits	Korea	27	<i>A. Arguta</i>	Fruits	Korea
08	<i>A. Polygama</i>	Vermiculate fruits	Korea	28	<i>A. Arguta</i>	Fruits	Korea
09	<i>A. Polygama</i>	Vermiculate fruits	Korea	29	<i>A. Arguta</i>	Fruits	Korea
10	<i>A. Polygama</i>	Vermiculate fruits	Korea	30	<i>A. Arguta</i>	Fruits	Korea
11	<i>A. Polygama</i>	Vermiculate fruits	Korea	31	<i>A. Arguta</i>	Fruits	Korea
12	<i>A. Polygama</i>	Vermiculate fruits	Korea	32	<i>A. Arguta</i>	Fruits	Korea
13	<i>A. Polygama</i>	Vermiculate fruits	Korea	33	<i>A. Arguta</i>	Fruits	China
14	<i>A. Polygama</i>	Vermiculate fruits	China	34	<i>A. Arguta</i>	Fruits	China
15	<i>A. Polygama</i>	Vermiculate fruits	China	35	<i>A. Arguta</i>	Fruits	China
16	<i>A. Polygama</i>	Vermiculate fruits	China	36	<i>A. Arguta</i>	Fruits	China
17	<i>A. Polygama</i>	Vermiculate fruits	China	37	<i>A. Arguta</i>	Fruits	China
18	<i>A. Polygama</i>	Vermiculate fruits	China	38	<i>A. Arguta</i>	Fruits	China
19	<i>A. Polygama</i>	Vermiculate fruits	China	39	<i>A. Arguta</i>	Fruits	China
20	<i>A. Polygama</i>	Vermiculate fruits	China	40	<i>A. Arguta</i>	Fruits	China

from Merck (Darmstadt, Germany). Dichloromethane and acetone (extra pure grade) were procured from Duksan Pure Chemicals Co., Ltd. (Ilsan, Republic of Korea). Formic acid (99.0%) was obtained from Daejung Chemicals & Metals co. Ltd. (Siheung, Republic of Korea).

**Instruments** – The HPTLC analysis was conducted using a CAMAG (Muttenez, Switzerland) equipment operated with visionCATS 3.2 software. The CAMAG equipment included a Linomat 5 applicator with a 100 µL syringe (Hamilton, Bonaduz, Switzerland) for sample application, TLC visualizer 3 for visualizing the chromatograms, TLC scanner 4 for quantification of the standard compound, automatic developing chamber (ADC) 2 with humidity control for the development of the chromatograms. Chromatographic separation was carried out on HPTLC Silica gel 60 plates (20 × 10 cm, Merck, Darmstadt, Germany) with F<sub>254</sub> fluorescent indicator for visualizing chromatograms. However, for scanning purposes, plates without the fluorescent indicator were used. For Mass spectrometry study, CAMAG TLC-MS-Interface was utilized to extract the compounds that can either differentiate MCRJ from MHD or are common to both, on the HPTLC plate and injected into the Mass spectrometer. A JMS-T100TD (AccuToF-TLC) mass spectrometer from JEOL Ltd., (Tokyo, Japan) was used, operating in Electrospray ionization (ESI) mode.

**Preparation of sample and standard solutions** – The samples were finely pulverized and then passed through an 850 µm sieve for particle size homogenization. Next, 4.0 g of each powdered sample was extracted with 10 mL methanol by sonication for 30 minutes (Powersonic 620, Hwashin Tech., Daegu, Republic of Korea). The extract was filtered using a filter paper (110 mm pore size, Hyundai micro, Republic of Korea) and subsequently evaporated under reduced pressure using a rotary evaporator (NVC-2100, EYELA, Japan). The residue was dissolved in 1 mL of methanol and filtered through a 0.45 µm polytetrafluoroethylene (PTFE) syringe filter. For the preparation of the standard solution, umbelliferone was precisely weighed and dissolved in methanol to achieve a concentration of 100 µg/mL. The standard solution was also filtered through a 0.45 µm PTFE syringe filter.

**HPTLC analysis conditions** – each applied as 2 µL, forming 8 mm bands spaced 4 mm apart and positioned 8 mm from the lower edge of the plate. The plate was then developed to a distance of 70 mm using a developing solvent system composed of dichloromethane-acetone-formic acid (4:1:0.1, v/v/v). Prior to development, the CAMAG glass twin through chamber (20 × 10 cm, CAMAG, Muttenez, Switzerland) was saturated for 20 minutes with a filter paper. The development process was conducted at a controlled temperature of 20 ± 5°C and

relative humidity of  $33 \pm 5\%$  using a saturated solution of  $MgCl_2$ . The developed plates were observed under a TLC visualizer under UV 366 nm. Subsequently, the plates were scanned at 330 nm in absorbance mode at 20 mm/s scanning speed, data resolution of 100  $\mu m$ /step, and slit size of  $5 \pm 0.2$  mm, micro. For obtaining UV spectra of umbelliferone between 200 and 450 nm in absorbance mode, a deuterium and tungsten lamp were used with a scanning speed of 20 mm/s and a slit size of  $5 \times 0.2$  mm, micro.

**MS analysis conditions** – For the MS analysis conducted in the positive ion mode, the parameters were set with a peak voltage of 1000 V, detector voltage of 2000 V, orifice 1 voltage of 40 V, orifice 1 temperature of 80°C, orifice 2 voltage of 10 V, and ring lens voltage of 5 V. The desolvating chamber was maintained at a temperature of 250°C.  $N_2$  gas is utilized at a flow rate of 1.0 L/min for nebulizing, and 3.0 L/min for desolvating. The acquired m/z range spanned from 50 to 1000. Before embarking on exact mass measurements, the mass scale was calibrated using the Yokudelna calibration kit from JEOL. The TLC-MS-interface extracted the targeted bands on the plate using a 1% acetic acid in 80% methanol solvent, with a flow rate of 0.1 L/min.


## Results and Discussion

The optimal HPTLC method was devised for the iden-

tification of MCRJ and MHD. Among the *Actinidia* species, only eleven coumarins have been reported, with umbelliferone confirmed exclusively in *A. polygama*.<sup>17,18</sup> As a result, we chose umbelliferone as the marker compound to differentiate MCRJ from MHD. The most effective mobile phase ensuring the appropriate retardation factor ( $R_f$ ) value for umbelliferone and clear separation was a mixture of dichloromethane-acetone-formic acid (99.0%) in a ratio of 4:1:0.1 (v/v/v).


To assess the consistency across individual HPTLC plates, an SST was executed using UHM. Under the prescribed HPTLC conditions, the chromatogram of HM was distinctly visible at UV 254 nm. Among the observed spots, the four most pronounced were selected as reference bands in ascending order based on their  $R_f$  value. The reference  $R_f$  values for these spots were established at 0.047, 0.339, 0.765, and 0.900, respectively, with the  $R_f$  values of each spot observed to deviate by no more than 0.02  $R_f$  units. Detailed results from the SST are available in the supplementary data (Table S1 and Fig. S2).

The developed HPTLC analysis unveiled unique fingerprints for both MCRJ and MHD, presenting a dependable method for distinguishing these two herbal medicines. As depicted in Fig. 2, a blue fluorescent band at an  $R_f$  0.610, consistent with umbelliferone, was observed in all 20 samples of MCRJ under UV 300 nm. This zone was absent in the 20 samples of MHD. Upon examining the UV spectra of the blue fluorescent band ( $R_f$  0.610) in



**Fig. 2.** HPTLC chromatogram of MCRJ (1-20) and MHD (21-40) analyzed with the proposed method under UV 366 nm; S, Umbelliferone (100  $\mu g/mL$ ).


the chromatograms of both the standard and samples using the TLC scanner, we found that their profiles closely matched each other, as illustrated in Fig. 3. This can be attributed to the traditional use of MCRJ for the treatment of rheumatoid arthritis and gout, stemming from umbelliferone's anti-rheumatic effects and its potent inhi-



**Fig. 3.** UV spectra of umbelliferone standard band and the blue fluorescent band in sample solution.

bitory effect on lipopolysaccharide (LPS)-induced inflammatory bone loss.<sup>19,20</sup>

In a further exploration of the HPTLC fingerprints using the TLC-MS-interface, we sought to elucidate mass information of bands that distinguish MCRJ from MHD and those that are shared between the two. To conduct the MS analysis, both MCRJ and MHD samples, each of 8  $\mu$ L, were placed on a single plate with 8 mm band length, and then processed according to the proposed method. As shown in Fig. 4, our focus was directed towards three specific bands: a turquoise fluorescent band at  $R_f$  0.82 (A) found only in MCRJ, a red-colored band at  $R_f$  0.51 (B) that appeared in both MCRJ and MHD, and a faint blue band at  $R_f$  0.38 (C) that was unique to MHD. In the ESI-MS in positive mode, distinct characteristic ions were observed. Band (A) displayed ions  $[M+Na]^+$  at  $m/z$  189.08607 and  $[2M+Na]^+$  and  $m/z$  355.18671. For band (B), the ion  $[M+Na]^+$  was detected at  $m/z$  191.10204, and band (C) showed  $[M+H]^+$  at  $m/z$  353.26579 and  $[M+Na]^+$  at  $m/z$  375.24909. Upon consulting a review on the compounds found in *Actinidia* species<sup>17</sup>, it was inferred that band (A), represented by  $C_{10}H_{14}O_2$ , could be either actinidialactone or neonepetalacotone. Meanwhile, band (B) with the molecular formula  $C_{10}H_{16}O_2$  was potentially



**Fig. 4.** ESI-TOF-MS spectra of the three bands in chemical fingerprints of MCRJ and MHD; a turquoise fluorescent band at  $R_f$  0.82 (A), a red-colored band at  $R_f$  0.51 (B), and a faint blue band at  $R_f$  0.38 (C).

indicative of dihydronepetalactone, iridomyrmecin, or isoiridomyrmecin.<sup>17,21</sup> However, a substance bearing the molecular formula  $C_{21}H_{36}O_4$ , as observed in band (C), has not been reported in plants of the *Actinidia* genus.

To comprehend the current content of umbelliferone in commercially available MCRJ, a quantification evaluation was carried out. For the calibration curve, 100  $\mu\text{g/mL}$  umbelliferone standard solution stock underwent serial dilutions using methanol, resulting in concentrations of 3.125, 6.25, 12.5, 25, and 50  $\mu\text{g/mL}$ . Each of these five concentrations was applied three times on a single HPTLC plate. The area corresponding to various concentrations of umbelliferone was measured and the resulting calibration curve showed remarkable linearity (Table 2).


The content ( $\mu\text{g/g}$ ) of umbelliferone in MCRJ was calculated from the linearity curve (Table 3). The average of 20 samples was 2.92  $\mu\text{g/g}$ . However, the Box plot depicted in Fig. 5 reveals a broad distribution of umbelliferone content, with a standard deviation (SD) of 3.00.

Particularly, samples 17 and 19 stand out as outliers in the entire data set. When these outliers are excluded, the mean content of umbelliferone is 2.12  $\mu\text{g/g}$ , with SD of 1.70. For the Korean MCRJ samples ( $n=13$ ), there was minimal fluctuation in content, with an average of 1.45  $\mu\text{g/g}$ , indicating that umbelliferone content was lower than Chinese MCRJ samples. However, for the Chinese

**Table 2.** Results of least square regression analysis for the quantitation of Umbelliferone ( $n=3$ )

Parameters	Normal-Phase HPTLC
linearity range ( $\mu\text{g}/\text{band}$ )	3.125 – 50
Regression equation	$y = 0.0006x + 0.001$
$R^2$	0.9987
Slope (mean $\pm$ SD)	$0.00062 \pm 0.00001$
Intercept (mean $\pm$ SD)	$0.00103 \pm 0.00003$
<sup>a</sup> confidence limit of slope	$0.0005784 - 0.0006610$
<sup>a</sup> confidence limit of intercept	$0.0009814 - 0.001064$

<sup>a</sup> 95% confidence limit



**Fig. 5.** The box plots of umbelliferone contents in MCRJ samples.

**Table 3.** The area and content of umbelliferone in MCRJ samples

Sample No.	1	2	3	4	5	6	7	8	9	10
Area	0.0018	0.0053	0.0022	0.0036	0.0053	0.0053	0.0045	0.0017	0.0053	0.0045
Content ( $\mu\text{g/g}$ )	0.32	1.77	0.48	1.08	1.78	1.79	1.42	0.29	1.77	1.46
Sample No.	11	12	13	14	15	16	17	18	19	20
Area	0.0096	0.0076	0.0021	0.0068	0.0176	0.0043	0.0294	0.0114	0.0218	0.0112
Content ( $\mu\text{g/g}$ )	3.56	2.74	0.45	2.41	6.84	1.38	11.73	4.31	8.59	4.22

samples, further investigation is required because the number of samples is not sufficient to reflect their variability.

In conclusion, using the proposed HPTLC method, the chemical profiles of MCRJ and MHD can be quickly and easily verified and compared, and offers a practical and effective tool for ensuring the quality and authenticity of MCRJ in the herbal market. This research could serve as a foundation for quality assessment in the drug development process using MCRJ with further studies on the content criteria of umbelliferone and bioactivities of MCRJ.

### Acknowledgments

This study was funded by a grant (00000MFDS000) from the Ministry of Food and Drug Safety in 2022-2023.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### References

- (1) Li, Y.; Shen, Y.; Yao, C. L.; Guo, D. A. *J. Pharm. Biomed. Anal.* **2020**, *185*, 113215.
- (2) Panishcheva, D.; Motyleva, S.; Kozak, N. *Slovak J. Food Sci.* **2021**, *15*, 723-731.
- (3) Takahashi, W.; Sugawara, F.; Yamamoto, N.; Bando, E.; Matsushita, J.; Tanaka, O. *J. Forest Res.* **2004**, *9*, 85-88.
- (4) Herbal Medicine Policy Division. Korean Herbal Pharmacopoeia; Ministry of Food and Drug Safety, Korea, **2022**.
- (5) Ren, J.; Han, E. J.; Chung, S. H. *Arch. Pharm. Res.* **2007**, *30*, 708-714.
- (6) Shizhen, L. *Bon Cho Gang Mok: Compendium of materia medica*; ChungKuK ChungEuiHak: China, **1978**.
- (7) Yoon, S.; Kim, H. *Donguibogam*; Donguibogam Publishing Company: Korea, **2006**, pp 297-2189.
- (8) Khromykh, N. O.; Lykholat, Y. V.; Didur, O. O.; Sklyar, T. V.; Davydov, V. R.; Lavrentieva, K. V.; Lykholat, T. Y. *Biosystems Diversity* **2022**, *30*, 39-45.
- (9) Di, X.; Chan, K. K.; Leung, H. W.; Huie, C. W. *J. Chromatogr. A* **2003**, *1018*, 85-95.
- (10) Goswami, A. K.; Gogoi, N.; Shakya, A.; Sharma, H. K. *J. Chromatogr. Sci.* **2019**, *57*, 411-417.
- (11) Liang, Y. Z.; Xie, P.; Chan, K. *J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **2004**, *812*, 53-70.
- (12) Nicoletti, M. *Rev. Bras. Farmacogn.* **2011**, *21*, 818-823.
- (13) Champati, B. B.; Padhiari, B. M.; Ray, A.; Jena, S.; Sahoo, A.; Sahoo, T.; Panda, P. C.; Nayak, S. *Plant Science Today* **2023**, *10*, 345-353.
- (14) Rodríguez-Valdovinos, K. Y.; Salgado-Garciglia, R.; Vázquez-Sánchez, M.; Álvarez-Bernal, D.; Oregel-Zamudio, E.; Ceja-Torres, L. F.; Medina-Medrano, J. R. *Plants* **2021**, *10*, 475.
- (15) Do, T. K. T.; Schmid, M.; Phanse, M.; Charegaonkar, A.; Sprecher, H.; Obkircher, M.; Reich, E. *J. Chromatogr. A* **2021**, *1638*, 461830.
- (16) Schmid, M.; Do, T. K. T.; Trettin, I.; Reich, E. *J. Chromatogr. A* **2022**, *1666*, 462863.
- (17) Ma, J. T.; Li, D. W.; Liu, J. K.; He, J. *Nat. Prod. Bioprospect.* **2021**, *11*, 537-609.
- (18) Lu, J.; Cui, G.; Wang, X.; Zhu, N.; Liu, G.; Li, X.; Jin, Y. *Chinese Pharmaceutical Journal* **2009**, *44*, 328-330.
- (19) Cai, L.; Zhou, M. Y.; Hu, S.; Liu, F. Y.; Wang, M. Q.; Wang, X. H.; Jiang, F.; Feng, X. W.; Liu, X. S.; Li, R. *Am. J. Chin. Med.* **2022**, *50*, 1945-1962.
- (20) Kwak, S. C.; Baek, J. M.; Lee, C. H.; Yoon, K. H.; Lee, M. S.; Kim, J. Y. *Int. J. Biol. Sci.* **2019**, *15*, 2427-2437.
- (21) Bol, S.; Scaffidi, A.; Bunnik, E. M.; Flematti, G. R. *BMC Biol.* **2022**, *20*, 192.

Received August 24, 2023

Revised August 31, 2023

Accepted September 07, 2023

## Legends of Supplementary data

**Table S1.** The result of system suitability test (SST)


Substance	Relative $R_f$ difference of the substance
[a]	$0.047 \pm 0.010$
[b]	$0.339 \pm 0.010$
[c]	$0.765 \pm 0.017$
[d]	$0.900 \pm 0.017$

**Fig. S1.** Morphological features of MCRJ samples.





Fig. S2. Morphological features of MHD samples.



**Fig. S3.** The result of system suitability test (SST) on three different plates. (A), (B), and (C) show that SST can be used as reference for adjustment of  $R_f$  shift.